1

Kim A. Heidenreich, PhD. CURRICULUM VITAE

Professor, Department of Pharmacology University of Colorado School of Medicine PO Box 6511, Mail Stop 8303 Aurora, CO 80045-0511 Phone: (303) 724-3602 FAX: (303) 724-3663 E-mail: kim.heidenreich@ucdenver.edu

Education: 1970-1974 B.S. degree in Biology, Westminster College, New Wilmington, PA 1974-1979 Ph.D. degree, Department of Physiology and Biophysics, University of Vermont, Burlington,

VT; Dr. Edith Hendley, thesis advisor 1979-1981 Postdoctoral fellow, Department of Pharmacology, University of Colorado Health Sciences

Center, Denver, CO; Dr. Perry Molinoff, mentor 1981-1983 Postdoctoral fellow, Division of Endocrinology, University of Colorado Health Sciences

Center, Denver, CO; Dr. Jerrold Olefsky, mentor Professional experience: 1983 Instructor, Department of Pharmacology, University of Colorado Health Sciences Center,

Denver, CO 1983-1989 Assistant Professor, Department of Medicine, University of California, San Diego, La Jolla,

CA 1989-1991 Associate Professor, Department of Medicine, University of California, San Diego, La Jolla,

CA 1991-1999 Associate Professor, Department of Pharmacology, University of Colorado Health Sciences

Center, Denver, CO 1999-present Professor, Department of Pharmacology, University of Colorado Health Sciences Center,

Denver, CO 2000-2010 Medical Research Career Scientist, Denver VA Medical Center Research interests: Neurodegenerative diseases and traumatic brain injury. Developing FLAP inhibitors for mitigating brain injury and neurological deficits resulting from TBI Academic honors and awards: 1973-1974 Biological Honorary Society, Westminster College 1974 Graduated cum laude from Westminster College 1974-1978 University of Vermont Teaching Fellowship 1980-1982 National Research Service Award from NIH 1986-1989 Career Development Award from Juvenile Diabetes Foundation 2000-2010 VA Career Scientist Award 2005-2006 UCDHSC Graduate School Dean’s Mentoring Award 2012 UC Denver Center for Neuroscience Translational Research Award Media interviews: 2013 Interviewed by Science magazine, “NFL Kicks Off Brain Injury Effort”, April 2, 2013 2013 W3W3 radio interview by Larry Nelson “Pharmacological Interventions for Mitigating and

Preventing Secondary Brain damage after TBI”. 2014 “NFL Players Kick Off Concussion Summit Super Bowl Week Despite Ongoing Litigations”,

Nicole Fisher, Forbes, Feb 5, 2014

2

2014 Interviewed by Molly Armbrister at BizWest News article about collaboration with Colorado Center for Drug Discovery on FLAP inhibitors in TBI, May 22, 2014.

2014 Interviewed by Libby Smith, CBS news, about our discovery that FLAP inhibitors significantly reduce secondary brain injury and neurological deficits resulting from TBI, September, 17, 2014.

Professional societies: 1981-present Society for Neuroscience 1983-1997 American Diabetes Association 1987-2011 Endocrine Society 1994-2011 International Society for IGF Research 2003-present RMRNG-Rocky Mountain Regional Neuroscience Group 2012-present National Neurotrauma Association 2012-present Women in Neurotrauma Research 2013 The American TBI Association National committees and grant review panels: 1986-present Ad hoc reviewer, National Science Foundation 1987-1991 Member of Medical Science Review Committee, The Juvenile Diabetes Foundation

International 1987-2001 Outside reviewer, Veterans Administration Merit Review Board 1991 Ad hoc reviewer, Swiss National Science Foundation 1995 Grant reviewer, Michigan Diabetes Research & Training Center 1996 Special Study section, Endocrinology NIH ZRG2-REB-1 1998 Endocrine Society Scientific and Educational Program Task Force 1999 Ad hoc, Endocrinology study section, NIH 2000 Public Policy Forum on Department of Defense’s Investment in Parkinson’s Research 2001-2002 Organizing committee, 8th International Meeting on Neural Transplantation and Repair 2001 Department of Defense Sponsored Parkinson’s Related Research, panel discussion 2001-2004 VA Merit Review, Neurobiology D study section 2001 Ad hoc grant reviewer, Virginia Center on Aging 2001-2004 Annual Meeting Steering Committee, Endocrine Society 2005-2008 President, RMRNG chapter of the Society for Neuroscience 2007 Ad hoc member, Scientific Advisory Board Meeting, Keystone Symposium on Molecular and

Cellular Biology 2008-2009 Member, Scientific Advisory Board Meeting, Keystone Symposium on Molecular and Cellular

Biology 2008 VA William S. Middleton Award review 2009-present Chair, Neurobiology section, Scientific Advisory Board Meeting, Keystone Symposium on

Molecular and Cellular Biology 2013 Invited Speaker and Scientist Panel, C4CT Concussion Awareness Summit, Brewer Sports

Symposium, Minneapolis, MN 2014 Invited Speaker and Scientist Panel, Pre-Superbowl C4CT Concussion Awareness Summit,

United Nations, New York, NY 2014 Invited to participate/speak at the International State-of-the-Science Meeting on Biomedical

Basis for mTBI Environmental Sensors, Booz Allen Hamilton Conference Center, McLean, VA, November 4-7, 2014.

Editorial work: 1983-Present Ad hoc reviewer: Science, Journal of Clinical Investigation, Journal of Biological Chemistry,

Endocrinology, Diabetes, Acta Endocrinology, Brain Research, Proceedings of the National Academy of Science, Developmental Neuroscience, Molecular Endocrinology, Regulatory Peptides, Neuroscience, J.Neuroscience, J.Neurochemistry, Nature Neuroscience, EMBO Journal, Autophagy

3

Teaching: 1975-1979 Lecturer and lab instructor in Human Physiology course, School of Medicine, University of

Vermont 1981-1983 Lecturer in Pharmacology 620, School of Medicine, University of Colorado Health Sciences

Center 1984-1991 Lecturer in Biology 151, Undergraduate School, University of California, San Diego 1986-1991 Course Director and Lecturer in Physiology/Pharmacology 218, School of Medicine,

University of California, San Diego 1992-2006 Lecturer in Medical Pharmacology 6000, School of Medicine, UCHSC 1992-2000 Discussion leader in Molecular Pharmacology, School of Medicine, UCHSC 1993-present Lecturer in Dental School Basic Science 6602, Dental School, UCHSC 1994-2005 Lecturer in Pharmacology 7620, School of Medicine, UCHSC 1998-2000 Lecturer in Graduate Pharmacology Course, UCHSC 1999-2003 Lecturer in Biomedical Sciences Core Course 7800, UCHSC 1994-present Member, Pharmacology Graduate Training Program, UCDHSC 1999-present Member, Biomedical Sciences Graduate Training Program, UCHSC 1999-present Member, Neuroscience Training Program, UCHSC 2000-present Member, Medical Sciences Training Program (MSTP), UCHSC 2003-present Lecturer, PHCL 7600, Frontiers in Pharmacology, UCHSC 2004-present Lecturer, PHCL 7606, Receptors and Cell Signaling, UCHSC 2007 MSTP tutorial, PHCL 7606, Receptors and Cell Signaling, UCDHSC 2006-present Lecturer, Life Cycle Section-School of Medicine Course Number IDPT 6003 2010-present Discussion leader, Ethics in Research PHCL 7605 Research/training support: Active CO-TBI Trust Fund (PI: Heidenreich) 7/01/12 – 6/31/14 Colorado Dept. of Human Services “Developing Novel 5-lipoxygenase Activating Protein (FLAP) Inhibitors for Use in TBI” Funds are requested for medicinal chemistry, structure-based drug design, in vitro screening, and evaluation of drugs in a rodent model of TBI. R25GM097633 (PIs: Restrepo/Serrano, Mentor: Heidenreich) 7/01/12 – 5/31/13 National Institutes of Health “Blueprint Program for Enhancing Neuroscience Diversity through Undergraduate Research Education Experience” Funds support a stipend and research supplies for BRAiN scholar Antoinette Foster. NIH-R21 4/21/13 - 3/31/15 National Institutes of Health (PI: Heidenreich) “Preclinical investigation of 5-lipoxygenase-activating protein (FLAP) inhibitors for traumatic brain injury.” Funds are requested for examining the efficacy and BBB permeability of MK-591 in a rodent model of TBI. Studies will also define the therapeutic window available for using FLAP inhibitors for TBI. 2013 Drug Discovery Research Project (PI: Heidenreich) 6/1/13 - 5/31/14 Colorado Center for Drug Discovery “Development of FLAP inhibitors for TBI” Funds are provided for medicinal chemistry support related to FLAP inhibitors for CNS use. CCTSI TL1 Program (Mentor:Heidenreich) 10/1/13 - 9/30/14 CTSA/NIH “Targeting leukotriene-mediated neuroinflammation in traumatic brain injury”. Stipend for Chelsea Corser-Jensen (3rd yr Neuroscience graduate student).

4

Pending CO-TBI Trust Fund (PI: Heidenreich) 7/01/15 – 6/31/17 Colorado Dept. of Human Services “Long-term complications of concussion and potential treatment”. Funds are requested to determine the role of neuroinflammation in the long-term complications of concussion and to examine the efficacy of FLAP inhibitors in blocking prolonged inflammation after mild TBI. Past support (3 yrs) CCTSI CNS Collaborative Research Award (PI: Heidenreich) 1/30/12 – 1/29/12 University of Colorado Denver School of Medicine “Developing novel 5-lipoxygenase-activating protein (FLAP) inhibitors for traumatic brain injury.” Funds are requested for medicinal chemistry, structure-based drug design, in vitro screening, and evaluation of drugs in a rodent model of TBI Pharmacology Translational Research Pilot Project (PI:Heidenreich) 2/01/11-until expended University of Colorado Denver School of Medicine “Blockade of the 5-LO Pathway in TBI” These studies will examine if 5-LO knockout mice are protected from secondary injury after TBI. Academic Enrichment Fund Award (PI: Heidenreich) 1/01/12 – 12/31/12 University of Colorado Denver School of Medicine “Targeting the 5-lipoxygenase pathway in TBI” These studies will determine if MK-886, a FLAP inhibitor that blocks leukotriene synthesis, attenuates edema and blood-brain-barrier disruption following fluid percussion injury in rats. F32-NS062534-01A1 (Mentor:Heidenreich) 07/01/08 – 07/31/11 NIH/NINDS “Regulation of Autophagic Cell Death in Neurons” The major goal of this fellowship is to develop live-cell imaging techniques to investigate autophagy in neurons. #08IHA00716 (PI:Heidenreich) 6/24/08 - 6/30/10 Colorado Dept of Human Services “The Role of Leukotrienes in TBI” These studies investigate the role of leukotrienes in the pathogenesis of traumatic brain injury and will determine if inhibitors of leukotriene synthesis can block brain injury induced by TBI. Merit Award (PI:Heidenreich) 4/1/05 - 3/31/10 Department of Veterans Affairs "Autophagic Cell Death and Neurodegeneration” The major goals of this project are to understand cell signaling pathways that regulate autophagic cell death of neurons. Career Scientist Award (PI:Heidenreich) 4/1/05 – 3/31/10 Department of Veterans Affairs Salary support for PI. Patents: Use of protein kinase inhibitors to treat neurodegenerative diseases, United States Patent #09/469,980

The use of FLAP inhibitors to reduce the effects of injury to the central nervous system, United States Patent # 61/935,763

Training experience: Graduate students and postdoctoral fellows 1988-1991 Kathleen Kenner, Ph.D. thesis research 1988 Pilar Mayor, Ph.D., postdoctoral research 1988-1990 Regina Moises, M.D., postdoctoral research 1993-1994 Ragaa Ibrahim-Schneck, Ph.D., postdoctoral research

5

1997-1999 Pravin Rao, Tulane University, honors program 1999 Carol Sable, Ph.D., postdoctoral research 1998-2000 Kris Himmerick,M.S. masters thesis research 1999-2001 Mingtao Li, Ph.D., postdoctoral research 1999-2000 Xiaomin Wang, M.S., visiting scholar 1999 Jennifer Monks, Ph.D., postdoctoral research 2000-2005 Ferogh Almadi, doctoral thesis research 2000-2004 Daniel Linesman,Ph.D., postdoctoral research 2000-2004 Maria McClure,Ph.D. doctoral thesis research 2000-2002 Reid Phelps, Denver University honors program 2001-2002 Brandon Cornejo, Medical Scientist Training Program, thesis research 2002-2005 Brent Butts, Ph.D., postdoctoral research 2002 Chris Bartley, Yale University honors program 2003-2004 Chunhe Chen, Ph.D., postdoctoral research 2003-2008 Thomas Precht, doctoral thesis research, Pharmacology program, UCDHSC 2003-2005 Angela Zimmerman, doctoral thesis research 2006-2009 Santiago Farias, doctoral thesis research, Neuroscience program, UCDHSC 2007-2010 Vincent Zaegel, Ph.D., postdoctoral research 2007-2010 Mona Bains, Ph.D., postdoctoral research 2011-2013 Predrag Serbedzija, Ph.D., post-doctoral research 2012-present Chelsea Corser-Jensen, doctoral thesis, Neuroscience Program and CCTSI clinical research

program, UC Denver/AMC 2014-present Alyssa Blood, Medical Student Research Track, UC Denver School of Medicine Supervised research rotations 1985 Alison Gilmore, Minority Access to Research Careers, UCSD 1986 April Cramer, Department of Biology, UCSD 1987 Genevieve DeVellis, Department of Biology, UCSC 1987 Kathy Kenner, Physiology/Pharmacology graduate program, UCSC 1988 Kathy Rasmussen, Physiology/Pharmacology graduate program, UCSD 1989 Don Kaduda, Physiology/Pharmacology graduate program, UCSD 1994 Marc Hurlbert, Pharmacology graduate program, UCHSC 1994-1995 April Cramer, NIH Minority Student Research Apprenticeship, UCHSC 1995 Jared Cobb, NIH Minority Student Research Apprenticeship, UCHSC 1996 Juni Mathai, Research Internship, University of Colorado at Denver 1995-1996 Alison Bauer, Pharmacology graduate program, UCHSC 1996-2001 Pravin Rao, NIH Minority Student Research Apprenticeship, UCHSC 1997 Kristine Rohde, Research Internship, University of Colorado at Denver 1997 Sarah Calvert, summer student Cancer Fellowship, UCHSC 1997 Jilla Sabetti, Pharmacology graduate program, UCHSC 1997 Amy Brown, Pharmacology graduate program, UCHSC 1998 Zachary Johnson, Biomedical Sciences Graduate Program, UCHSC 1999 Kris Himmerick, Biomedical Sciences Graduate Program, UCHSC 1999 Sun-Young Han, Biomedical Sciences Graduate Program, UCHSC 1999 Pravin Rao, honors project, University of Tulane 1999 Sue Hong, undergraduate research volunteer, University of Colorado 1999 Carrie Hinks, Biomedical Sciences Internship, UCHSC 2000 Maria McClure, Pharmacology graduate student, UCHSC 2000 Lone Veng, Neuroscience graduate student, UCHSC 2001 Brandon Cornejo, MSTP student, UCHSC 2002 Tom Precht, Pharmacology graduate student, UCHSC 2003 Frances (Alex) Loucks, undergraduate research, Vassar College 2003 Angela Zimmermann, Neuroscience graduate student, UCHSC 2003 Evan Green, UCHSC Cancer Center Summer Research fellowship 2004 Holly Hunter, Pharmacology graduate student, UCHSC 2005 Rebekah Vest, Pharmacology graduate program, UCHSC

6

2006 Meredith Ackerman, Kent Denver School, Denver, CO 2006 Jill Neiman, MSTP student, UCDHSC 2009 Nelitza Rivera Vega, NIH Gems Program and Endocrine Society Undergraduate Research

Program, University of Puerto Rico at Cayey 2011 Dayton Goodell, NIH Building Research Achievement in Neuroscience (BRAiN) Training

Program, University of Colorado Denver 2011 Chelsea Jensen-Corser, Neuroscience graduate student, UCDenver/AMC 2012 Antoinette Foster, NIH Building Research Achievement in Neuroscience (BRAiN)

Training Program 2012 Dayton Goodell, Neuroscience graduate student, UC Denver/AMC 2013 Taylor Soderburg, Medical Scientist Training Program, UC SOM/AMC 2014 Alicia Purkey, Pharmacology graduate student, UC SOM/AMC Thesis advisory committees 1985-1986 John Bell, Physiology/Pharmacology graduate program, UCSD 1986-1990 Gary Heiserman, Physiology/Pharmacology graduate program, UCSD 1993-1996 Janice Gleavy, Pharmacology graduate program, UCHSC 1994-1998 Ron Leikteig, Pharmacology graduate student, UCHSC 1996-1999 Marc Hurlbert, Pharmacology graduate student, UCHSC 1999-2003 Amy Brown, Pharmacology graduate student, UCHSC 1999-2004 Xioxin Wang, Neuroscience graduate student, UCHSC 1999-2003 Steve Rosinski, MSTP program, UCHSC, Chair 2000-2004 Christine Hoyt, Immunology graduate student, UCHSC 2001-2003 Sun-Young Han, Pharmacology graduate student, UCHSC 2002-2003 Sarah Burns-Richardson, Neuroscience graduate student, UCHSC 2002-2003 Brian Tunquist, Pharmacology graduate student, UCHSC 2006-2010 Faye Doherty, Neuroscience graduate student, UCDHSC 2006-2007 Aaron Emerson, Pharmacology graduate program, UCHSC 2007-2010 Rebekah Vest, Pharmacology graduate student, UCDHSC 2007-2008 Brittany Allen, Cell and Developmental Biology program, UCDHSC 2007-2010 David Cantu, Neuroscience graduate program, UCDHSC 2012-present Jacki Rorabough, Pharmacology graduate program, UC Denver, AMC 2012-present Shane Rowley, Neuroscience graduate program, UC Denver/AMC Graduate program examination committees 1987 Adrienne Harris, Physiology/Pharmacology graduate program, UCSD 1987 Ellen Potter, Physiology/Pharmacology graduate program, UCSD 1987 Steve Okino, Physiology/Pharmacology graduate program, UCSD 1988 Jacque Dyck, Physiology/Pharmacology graduate program, UCSD 1988 Greg Lamb, Physiology/Pharmacology graduate program, UCSD 1988 Charlie Limoli, Physiology/Pharmacology graduate program, UCSD 1993 David Rose, Pharmacology graduate program, UCHSC 1994 Lisa Nickelson, Pharmacology graduate program, UCHSC 1996 Alex Hoffman, Pharmacology graduate program, UCHSC 1997 Alison Bauer, Pharmacology graduate program, UCHSC 1997 Marc Hurlbert, Pharmacology graduate program, UCHSC 1998 Katherine Lobel, Pharmacology graduate program, UCHSC 2000 Xioxin Wang, Neuroscience graduate program, UCHSC 2000 Aaron Spalding, Chair, Pharmacology graduate program, UCHSC 2000 Sun-Young Han, Chair, Pharmacology graduate program, UCHSC 2000 David Grosshan, MSTP program, UCHSC 2001 Stacy Blaine, Minor Proposal Mentor, Pharmacology graduate program, UCHSC 2001 Jason Tregallas, Comprehensive Exam, Pharmacology graduate program, UCHSC 2006 Rebekah Vest, Comprehensive Exam, Pharmacology graduate program, UCHSC 2006 Aaron Emerson, Comprehensive Exam, Pharmacology graduate program, UCHSC 2006 Faye Doherty, Comprehensive Exam Chair, Neuroscience graduate program, UCDHSC

7

2006 Anna Nelson, Major proposal, Pharmacology graduate program and MSTP, UCDHSC 2007 Brittany Allen, Comprehensive Exam, BSP graduate program, UCDHSC 2007 David Cantu, Comprehensive Exam, Neuroscience graduate program, UCDHSC 2009 Patrick Hutchins, Comprehensive Exam, Pharmacology graduate program, UCDHSC 2011 Jacki Rorabough, Comprehensive Exam, Pharmacology graduate program, UCDenver/AMC 2011-2014 Shane Rowley, Comprehensive Exam, Neuroscience graduate program, UC Denver/AMC Administration/service: 1990-1991 Chairman, Physiology/Pharmacology Minor Proposition Committee, UCSD 1990-1991 Physiology/Pharmacology Curriculum Committee, UCSD 1990-1991 Affirmative Action Representative for the Physiology/Pharmacology Graduate Program,

UCSD 1992-1996 Committee on Biosafety, Denver VAMC 1992-1995 VA Protocol Review Committee 1993 Abstract reviewer for the ADA 53rd Scientific Session 1994-1997 Board of Directors, Rocky Mountain Chapter of Juvenile Diabetes Foundation 1996-2011 Pharmacology Graduate Training Committee, UCHSC 1997 Sponsor, 1st place, Denver Metro Science Fair for high school students 1997-1999 Research & Development Committee, Denver VAMC 1999-2001 Chairman, Research and Development Committee, Denver VAMC 1997-present Department of Pharmacology Seminar Committee 1999-2001 UCHSC Faculty Promotions Committee 2000 Neuroscience Faculty Search Committee 2000 UCHSC Search Committee for Director of Molecular Biology Program 2001-2002 Co-chair, UCHSC Faculty Promotions Committee 2002-2003 School of Medicine Strategic Planning Committee 2003-2004 UCHSC Search Committee, Endowed Chair in Cancer Research 2003-2011 Department of Pharmacology Faculty Promotions and Tenure Committee 2004-present Department of Pharmacology Annual Report Committee 2006 Organized annual Rocky Mountain Regional Neuroscience Group Symposium (May18th) 2006-2012 Chair, UCHSC Neuroscience Program membership committee 2006-2008 Member, Senior Investigator Network (SINET), UCDHSC 2006-present Neuroscience Program executive committee 2007 UCHSC Evaluation Committee for Chancellor’s Bridge Funding Awards 2004-2008 NIH STEPS (Strides Toward Encouraging professions in Science) Program 2009 ASPET Summer Undergraduate Research Fellowship Program 2006-present Interview candidates for MSTP program 2010 School of Medicine Mentored Scholarly Activity (MSA) poster judge 2011-present Chair, Department of Pharmacology Promotion and Tenure Committee 2011-present Mentor, NIH Building Research Achievement training program Invited lectures: 1984 American Society of Pharmacology and Experimental Therapeutics, Indianapolis, IN 1986 III International Symposium on Insulin Receptors and Insulin Action, Madrid Spain 1986 La Jolla Cancer Research Foundation, La Jolla, CA 1986 American Diabetes Association Southern California Affiliate 2nd Annual Research

Symposium, Long Beach, CA 1987 Symposium on Insulin and Related Peptides in the CNS, Gainesville, FL 1987 Brain Neurochemistry Group and Department of Anatomy, UCLA, Los Angeles, CA 1988 Diabetes Research Center, University of Washington, Seattle, WA 1988 Department of Physiology, University of Vermont, Burlington, VT 1988 Symposium on the Action of Insulin and Related Growth Factors in Diabetes Mellitus, Joslin

Diabetes Center, Boston, MA 1989 Symposium on the Role of Insulin and IGF-I in the Central Nervous System, American

Society for Neurochemistry, Chicago, IL

8

1990 Department of Reproductive Medicine, USCD, La Jolla, CA 1991 Neuroscience Program, Colorado State University, Fort Collins, CO 1992 New York Academy of Sciences Conference on Insulin-Like Growth Factors in the Nervous

System, Washington, D.C. 1993 Department of Pharmacology, Wayne State University, Detroit, MI 1993 Department of Pharmacology, UCHSC, Denver, CO 1993 Program in Hormones and Cancer, UCHSC, Denver, CO 1994 Division of Clinical Pharmacology, UCHSC, Denver, CO 1994 Rocky Mountain Chapter, Juvenile Diabetes Foundation, Colorado Springs, CO 1995 Cell Cycle Meeting, UCHSC, Denver, CO 1995 Neuroscience Department, UCHSC, Denver, CO 1996 Keystone Symposium on Neural Peptides, Lake Tahoe, CA 1996 Barbara Davis Diabetes Center, Denver, CO 1997 Cell Cycle Meeting, UCHSC, Denver, CO 1997 Chairperson, plenary session "Mechanisms of Insulin Signaling", Endocrine Society meetings 1998 Endocrine Society Symposium speaker, New Orleans, LA 1999 Neuroscience Program, UCHSC, Denver, CO 1999 Plenary talk, American Federation for Medical Research, Carmel, CA 2000 Neuroscience Program, UCHSC, Denver, CO 2000 Division of Endocrinology, UCHSC, Denver, CO 2000 Program of Molecular and Cellular Pathology, University of Alabama, GA 2000 Joslin Diabetes Center and Harvard Medical School, Boston, MA 2000 Michael J. Fox Foundation for Parkinson’s Research, Washington, D.C. 2001 Danish Society for Neuroscience and Danish Society for Biochemistry and Molecular Biology,

Symposium on Molecular Mechanisms in Neuronal Degeneration, Copenhagen, Denmark 2001 Chairperson, Plenary Symposium on AKT and MAPK, The Endocrine Society 2002 Plenary talk, New York Academy of Science Symposium “ PD: Life Cycle of the Dopamine

Neuron”, Princeton, N.J. 2003 Chairperson and Invited Speaker, Gordon Conference on Insulin-like Growth Factors,

Ventura, CA 2003 Department of Pharmacology Retreat, Copper Mountain, CO, “Molecular Mechanisms of

Neuronal Death”, CO 2004 Neuroscience program, University of Michigan, Ann Arbor, “Molecular Mechanisms of

Neuronal Death”, MI 2005 Department of Pathology, University of Pittsburgh, Pittsburgh, PA, “ Molecular Mechanisms of

Neuronal Cell Death”, PA 2005 Invited symposium speaker, Gordon Conference on IGFs, “The Neuroprotective Actions of

IGFs, Ventura, CA 2006 Department of Neurology, “Mechanisms of Neuronal Cell Death”, Johns Hopkins University,

Baltimore, MD 2007 Invited speaker, Gordon Research Conference, Insulin-like Growth Factors in Physiology and

Disease, Venture, CA 2007 Department of Pharmacology, University of Texas Health Science Center, San Antonio, TX,

“Different Ways that Neurons Die”. 2007 Department of Physiology, Colorado State University, Fort Collins, CO, “ Apoptotic and

autophagic death of neurons”. 2008 Symposium organizer, Winter Conference for Brain Research, “New Pistes for IGF Signaling

in the Brain”, Salt Lake City, Utah. 2009 Gordon Research Conference, invited discussion leader, “IGFs in Physiology and Disease”,

Ventura, CA. 2009 DU 2nd Brain Injury Conference, Colorado TBI Trust Fund Forum, “Research in TBI”, Denver,

CO 2011 Department of Pharmacology, UC Denver, Aurora, CO. “Targeting the 5-lipoxygenase

pathway in TBI”. 2012 Neurology Grand Rounds, UC Denver, Anschutz Medical Campus, Aurora, CO. “Targeting

the 5-lipoxygenase pathway in TBI”.

9

2012 Pharmacology Retreat, Snow Mountain Ranch, Winter Park, CO. “Traumatic Brain Injury: The Need for Pharmacological Intervention”.

2013 CCTSI/Center for Neuroscience Translational Research Awardee Presentation, “Developing novel 5-lipoxygenase-activating protein (FLAP) inhibitors for traumatic brain injury”, UC Denver, AMC, Feb 12, 2013.

2013 3rd Annual Traumatic Brain Injury Conference, “Prevention of TBI-induced cognitive deficits using an inhibitor of leukotriene synthesis”. Washington, DC, March 6, 2013.

2013 Department of Pharmacology, UC Denver School of Medicine, “Inhibition of leukotriene production protects against secondary brain damage and cognitive deficits after TBI”. Aurora, CO, April 15, 2013.

2013 National Jewish Hospital, “Targeting the 5-lipoxygenase pathway in TBI”. Denver, CO, April 25, 2013.

2013 C4CT Concussion Awareness Summit, “FLAP Inhibitors for Prevention and Intervention of TBI”, Minneapolis, MN, June 21, 2013.

2013 Translational Research and Colorado Educator’s Conference, University of Denver, “FLAP inhibitors for the treatment and prevention of TBI”, September 27, 2013.

2013 Neurosurgery Grand Rounds, UC Denver School of Medicine, “Developing a novel anti-inflammatory drug to prevent and treat TBI”, Anschutz Medical Campus, Aurora, CO, October 8, 2013.

2013 Neuroscience Program Retreat, UC Denver School of Medicine, “Developing a novel anti-inflammatory drug to prevent and attenuate brain injury and neurological impairments after TBI”, Winter Park, CO, November 1, 2013.

2013 Brain Injury Research Group, UC Denver School of Medicine, Department of Pediatric Neurology, “Development of a novel, proprietary drug for preventing and attenuating brain damage and cognitive defects after TBI.” Anschutz Medical Campus, Aurora, CO, November 21, 2013.

2014 Pre-Superbowl C4CT Concussion Awareness Summit,” FLAP inhibitors for mitigating secondary brain injury and neurological deficits resulting from TBI”, United Nations, New York, NY, Jan 29, 2014.

2015 Keynote speaker, “Repurposing FLAP inhibitors for treating TBI” Excellence in Neurology Symposium sponsored by the National Association of Medical Advancement, Phoenix, Arizona, April 8-10, 2015.

Research publications: 1. Hendley ED, GH Burrows, ES Robinson, KA Heidenreich, CA Bulman: Acute stress and brain norepinephrine uptake mechanism in the rat. Pharmacol Biochem Behav 6:197-202, 1977.

2. Heidenreich KA, ED Hendley: Photoaffinity labeling of adrenergic receptors in neuronal membranes. IN: Catecholamines: Basic and Clinical Frontiers, E Usdin (ed), Pergamon Press, New York, NY, 1978.

3. Heidenreich KA, GA Weiland, PB Molinoff: Characterization of radiolabeled agonist binding to -adrenergic receptors in mammalian tissues. J Cyclic Nucl Res 6:217-230, 1980.

4. Molinoff PB, GA Weiland, KA Heidenreich, RN Pittman, KPM Minneman: Interactions of agonists and antagonists with -adrenergic receptors. Adv in Cyclic Nucl Res 14:51-67, 1981.

5. Zahniser NR, KA Heidenreich, PB Molinoff: Binding of 3H-amino-6,7-dihydroxy-1,2,3,4-tetrahydronapthalene to rat striatal membranes. Effects of purine nucleotides and ultraviolet irradiation. Mol Pharm 19:372-378, 1981.

6. Heidenreich KA, GA Weiland, PB Molinoff: Effects of magnesium and N-ethylmaleimide on the binding of 3H-hydroxybenzylisoproterenol to -adrenergic receptors. J Biol Chem 257:804-810, 1982.

10

7. Olefsky JM, S Marshall, P Berhanu, M Saekow, KA Heidenreich, A Green: Internalization and intracellular processing of insulin and insulin receptors in adipocytes. Metabolism 31:670-690, 1982.

8. Heidenreich KA, P Berhanu, JM Olefsky: Degradation of insulin receptors in rat adipocytes. Diabetes 32:1001-1009, 1983.

9. Heidenreich KA, NR Zahniser, P. Berhanu, JM Olefsky, D Brandenburg: Structural differences between insulin receptors in the brain and in peripheral target tissues. J Biol Chem 258:8527-8530, 1983.

10. Heidenreich KA, D Brandenburg, P Berhanu, JM Olefsky: Metabolism of photoaffinity labeled receptors by adipocytes: Role of internalization, degradation, and recycling. J Biol Chem 259:6511-6515, 1984.

11. Heidenreich KA, JM Olefsky: The metabolism of insulin receptors: Internalization, degradation, and recycling. IN: The Molecular Basis of Insulin Action, M Czech (ed), Plenum Publishing Corporation, New York, NY, pp. 45-65, 1985.

12. Marshall S, KA Heidenreich, H Horikoshi: Stoichiometric translocation of adipocyte insulin receptor from the cell-surface to the cell-interior : Studies using a novel method to rapidly remove detergent and concentrate receptors. J Biol Chem 260:4128-4135, 1985.

13. Heidenreich KA, C Yip, B Frank, JM Olefsky: The preparation and characterization of photoreactive analogs of insulin radiolabeled in the or chain. Biochem Biophys Res Comm 126:1138-1145, 1985.

14. Heidenreich KA, P Gilmore: Structural and functional characteristics of insulin receptors in rat neuroblastoma cells. J. Neurochem. 45:1642-1648, 1985.

15. Heidenreich KA, S Marshall: The internalization and intracellular processing of insulin receptors. IN: The Receptors, Vol.III, P Conn (ed.). Academic Press, New York, NY, pp. 331-354, 1986.

16. Heidenreich KA, D Brandenburg: Oligosaccharide heterogeneity of insulin receptors. Comparison of N-linked glycosylation of insulin receptors in adipocytes and brain. Endocrinology 118:1835-1842, 1986.

17. Hueckstaedt T, JM Olefsky, D Brandenburg, KA Heidenreich: Recycling of photoaffinity labeled insulin receptors in rat adipocytes. J Biol Chem 261:8655-8659, 1986.

18. Heidenreich KA, GR Freidenberg, DP Figlewicz, PR Gilmore: Evidence for a subtype of insulin-like growth factor I receptor in brain. Regulatory Peptides 15:301-310, 1986.

19. Heidenreich KA: Evidence for a subtype of insulin receptor in brain. IN: The Functional Aspects of Insulin and Insulin-Related Peptides: Implications for the Central Nervous System. M Raizada, D LeRoith (eds.), Plenum Publishing Corporation, New York, NY, pp. 177-190, 1987.

20. Heidenreich KA, PR Gilmore, D Brandenburg, E Hatada: Peptide mapping and Northern blot analysis of insulin receptors in brain and adipocytes. Mol Cell. Endocrinol. 56:255-261, 1988.

21. Heidenreich KA, G deVellis, PR Gilmore: Functional properties of the subtype of insulin receptor found on neurons. J Neurochem 51:878-887, 1988.

22. Heidenreich KA: The structure of insulin receptors in nervous tissue. IN: Receptor Biochemistry and Methodology: The Insulin Receptor, CR Kahn, LC Harrison (eds.), Alan R. Liss, Inc., New York, NY, pp. 281-292, 1988.

23. Heidenreich KA, PR Gilmore, WT Garvey: Characterization of glucose uptake in primary cultured neurons. J Neurosci Rev 22:1-9, 1989.

11

24. Heidenreich KA, SP Toledo: Insulin receptors mediate growth effects in cultured fetal neurons. I. Rapid stimulation of protein synthesis. Endocrinology 125:1451-1457, 1989.

25. Heidenreich KA, SP Toledo: Insulin receptors mediate growth effects in cultured fetal neurons. II. Activation of a protein kinase that phosphorylates ribosomal protein S6. Endocrinology 125:1458-1463, 1989.

26. Ciaraldi TP, A Gilmore, M Goldberg, KA Heidenreich: In vitro studies on the action of CS-045, a new anti-diabetic agent. Metabolism 39:1056-1062, 1990.

27. Moises RS, KA Heidenreich: Pertussis toxin catalyzed ADP-ribosylation of a 41 kDa protein impairs insulin-stimulated glucose metabolism in BC3H1 cells. J Cell Physiol 144:538-545, 1990.

28. Heidenreich KA, SP Toledo, LL Brunton, S Daniel-Issakani, B Strulovici: Insulin stimulates the activity of a novel protein kinase C, PKC-, in cultured fetal chick neurons. J. Biol. Chem. 265:15076-15082, 1990.

29. Heidenreich KA: Insulin in the brain: What is its role? IN: Trends in Endocrinology and Metabolism 2(1) Elsevier Science Publishing Co., Inc., New York, NY, pp. 9-12, 1991.

30. Heidenreich KA: Regulation of protein phosphorylation by insulin and insulin-like growth factors in cultured fetal neurons. IN: Molecular and Cellular Aspects of Insulin, IGFs, and their Receptors, M Raizada, D LeRoith (eds.), Plenum Publishing Corporation, New York, NY, pp. 379-384, 1991.

31. Kenner KA, KA Heidenreich: Insulin and insulin-like growth factors stimulate in vivo receptor autophosphorylation and tyrosine phosphorylation of a 70 kDa substrate in cultured fetal neurons. Endocrinology 129:301-311, 1991.

32. Zahniser NR, KJ Buck P Curella, SJ McQuilklin, D Wiseon Shaw, CL Miller, RL Klein, KA Heidenreich, WJ Keir, JM Sikela, RA Harris: GabaA receptor function and regional analysis of subunit mRNAs in long-sleep and short-sleep mouse brain. Mol Brain Res 14:196-206, 1992.

33. Moises RS, KA Heidenreich: Glucose regulates the expression of Gi-proteins in cultured BC3H1 myocytes. Biochem Biophys Res Comm 182:1193-1200, 1992.

34. Heidenreich KA, KA Kenner: Analysis of ligand-stimulated tyrosine phosphorylation in the nervous system. NeuroProtocols: A Companion to Methods in Neurosciences 1:232-239, 1992.

35. Heidenreich KA, LJ Robinson: Insulin and insulin-like growth factor I induce c-fos in postmitotic neurons by a protein kinase C-dependent pathway. J. Biol. Chem. 268:14663-14670, 1993.

36. Heidenreich KA: Insulin and IGF-I receptor signaling in cultured neurons. IN: Annals N.Y. Acad. Sci., vol. 262, M Raizada, D LeRoith (eds.), pp. 72-88, 1993.

37. Begum N, LJ Robinson, B Draznin, KA Heidenreich: Protein phosphatase 1 and 2A activities in cultured fetal chick neurons: Developmental expression and regulation by insulin. Endocrinology 133:2085-2090, 1993.

38. Heidenreich KA: Regulation of c-fos gene expression by insulin in neurons. IN: Molecular Biology of Diabetes II, B Draznin, D LeRoith (eds.), Humana Press, Inc. pp. 363-375, 1994.

39. Robinson LJ, W Leitner, B Draznin, KA Heidenreich: Evidence that p21ras mediates the neurotrophic effects of insulin and insulin-like growth factor I in chick forebrain neurons. Endocrinology 135:2568-2573, 1994.

40. Kenner KA, J Kusari, KA Heidenreich: cDNA sequence analysis of the human brain insulin receptor. Biochem Biophys Res Comm 217:304-312, 1995.

12

41. Kummer JL, WM Zawada, CR Freed, SD Chernausek, KA Heidenreich: Insulin-like growth factor binding proteins in fetal rat mesencephalic cultures: Regulation by fibroblast growth factor and insulin-like growth factor I. Endocrinology 137:3551-3556, 1996.

42. Heidenreich KA, JL Kummer: Inhibition of p38 mitogen-activated protein kinase by insulin in fetal neurons. J. Biol. Chem. 271:9891-9894, 1996.

43. Zawada WM, DL Kirschman, JJ Cohen, KA Heidenreich, CR Freed: Growth factors rescue embryonic dopamine neurons from programmed cell death. Exp. Neurology 140:60-67, 1996.

44. Carel K, J Kummer, C Schubert, W Leitner, KA Heidenreich, B Draznin: Insulin stimulates MAP kinase by a Ras-independent pathway in 3T3-L1 adipocytes. J. Biol. Chem. 271:30625-30630, 1996.

45. Kummer JL, P Rao, KA Heidenreich: p38 MAP kinase mediates apoptosis induced by trophic factor withdrawal. J Biol Chem 271:20490-20494, 1997.

46. Shapiro L, KA Heidenreich, MK Meintzer, CA Dinarello: Role of p38 mitogen activated protein kinase in human immunodeficiency virus type 1 production in vitro. Proc Natl Acad Sci USA, 95: 7422-7426, 1998.

47. Pugazhenthi S, T Boras, MK Meintzer, KA Heidenreich, JE-B Reusch: Insulin-like growth factor I-mediated phosphorylation and activation of CREB in PC12 cells. Multiple signaling pathways are involved. J Biol Chem 274: 2829-2837, 1999.

48. Allen MP, C Zeng, K Schneider, MK Meintzer, C Basilico, B Varnum, KA Heidenreich, ME Wierman. Growth arrest specific gene (Gas 6)/adhesion related kinase (ARK) signaling promotes gonadotropin releasing hormone (GnRH) neuronal survival via ERK and Akt. Mol. Endocrinology 13: 191-201, 1999.

49. Pugazhenthi S, E Miller, C Sable, P Young, KA Heidenreich, LM Boxer, J E-B Reusch. Insulin-like growth factor-I induces bcl-2 promoter through the transcription factor cAMP response element binding protein. J. Biol. Chem. 274: 27529-27535, 1999.

50. Pugazhenthi S, A Nesterova, C Sable, KA Heidenreich, LM Boxer, LE Heasley, J E-B Reusch. Akt/ Protein kinase B mediated cell survival involves transcriptional upregulation of bcl-2. J. Biol. Chem. 275: 10761-10766, 2000.

51. Li MT, X Wang, MK Meintzer, and KA Heidenreich. CAMP protects neurons from apoptosis by inhibiting GSK-3B activity in rat cerebellar granule neurons. Mol. Cell Biol. 20: 9356-9363,2000.

52. Zawada WM, MK Meintzer, C Sable, CR Freed, and KA Heidenreich. Inhibitors of p38 MAP kinase increase the survival of transplanted dopamine neurons. Brain Res. 891:185-196, 2001.

53. Clarkson, ED, WM Zawada, KP Bell, JE Esplen, PK Choi, KA Heidenreich, and CR Freed. IGF-I and bFGF improve dopamine neuron survival and behavioral outcome in parkinsonian rats receiving cultured human fetal tissue strands. Exp. Neurology 168:183-191, 2001.

54. Linseman DA, KA Heidenreich, and SK Fisher. Fyn tyrosine kinase links muscarinic receptor stimulation to phosphorylation of the CdC42 effector ACK-1. J. Biol. Chem. 276: 5622-5628, 2001.

55. Li M, DA Linseman, MP Allen, MK Meintzer, X Wang, T Laessig, ME Wierman, and KA Heidenreich. MEFA and MEF2D undergo phosphorylation and caspase-mediated degradation during apoptosis of cultured rat cerebellar granule neurons. J. Neuroscience 21 (17): 6544-6552, 2001.

56. Linseman DA, TA Laessig, M McClure, MK Meintzer, H Barth, K Aktories, and KA Heidenreich. Inhibition of Rac/Cdc42 function induces apoptosis of cerebellar granule neurons via a c-jun signaling pathway. J. Biol. Chem. 276: 39123-39131, 2001.

13

57. Allen, MP, DA Linseman, H Udo, M Xu, B Varnum, ER Kandel, KA Heidenreich, and ME Wierman. A novel mechanism for GnRH neuron migration involving Gas6/Ark signaling to p38 MAP kinase. Mol. Cell. Biol. 22 (2): 599-613, 2002.

58. Linseman, DA, ML McClure, RJ Bouchard, TA Laessig, D Brenner, and KA Heidenreich. Suppression of death receptor signaling in cerebellar Purkinje neurons protects neighboring granule neurons from apoptosis. J. Biol. Chem 277:24546-24553, 2002.

59. Linseman, DA, RA Phelps, RJ Bouchard, TA Laessig, SS Le, and KA Heidenreich. Insulin-like growth factor-I blocks Bim induction and intrinsic death signaling in cerebellar granule neurons. J. Neuroscience 22: 9287-9297, 2002.

60. Allen, MP, M Xu, DA Linseman, JE Pawlowski, GM Bokoch, KA Heidenreich, and ME Wierman Adhesion related kinase (ARK) repression of gonadotropin releasing hormone (GnRH) gene expression requires Rac activation of the extracellular signal-regulated kinase (ERK) pathway. J. Biol. Chem. 277: 38133-38140, 2002.

61. Wei S, F. Marches, B Daniel, S Sonda, KA Heidenreich, and T Curiel. Pyridinylimidazole p38 mitogen-activated protein kinase inhibitors block intracellular Toxoplasma gondii replication. .Int J Parasitol. 32(8):969-77, 2002.

62. Linseman, DA, BJ Cornejo, SS Le, MK Meintzer,, TA Laessig , RJ Bouchard, and KA Heidenreich. A novel mechanism for lithium neuroprotection involving suppression of myocyte enhancer factor 2D hyperphosphorylation and degradation. J.Neurochem.. 85: 1488-1499, 2003.

63. Heidenreich KA. Molecular Mechanisms of Neuronal Cell Death. In Parkinson’s Disease, Annals of the New York Academy of Sciences, vol.991, 237-250, 2003.

64. Linseman, DA, CM Bartley, SS Le, TA Laessig , RJ Bouchard, MK Meintzer, M Li, and KA Heidenreich. Inactivation of the MEF2 repressor HDAC5 by endogenous CAMKII promotes depolarization-mediated neuronal survival. J. Biol. Chem. 278: 41472-41481, 2003.

65. Ahmadi F, DA Linseman , TN Grammatopoulos, RJ Bouchard, SM Jones, CR Freed, KA Heidenreich, and WM Zawada. The pesticide rotenone induces caspase-3 mediated apoptosis in ventral mesencephalic dopaminergic neurons. J. Neurochem. 86: 914-921, 2003.

66. Butts BD, DA Linseman, SS Le, TA Laessig , and KA Heidenreich. Insulin-like growth factor-I suppresses degradation of the pro-survival transcription factor myocyte enhancer factor 2D (MEF2D) during neuronal apoptosis. Horm. Metab. Res.35: 763-770, 2003.

67. Heidenreich KA and DA Linseman. Myocyte enhancer factor-2 (MEF2) transcription factors in neuronal differentiation and survival. Mol. Neurobiol. 29: 155-166, 2004.

68. McClure ML, DA Linseman, CT Chu, RJ Bouchard, TA Laessig, SS Le, and KA Heidenreich. Neurotrophins and death receptors regulate autophagic death in cerebellar Purkinje neurons. J. Neuroscience 24: 4498-4509, 2004.

69. Linseman, DA*, BD Butts*, TA Precht, RA Phelps, SS Le, TA Laessig, RJ Bouchard, ML McClure, and KA Heidenreich. Glycogen synthase kinase-3b phosphorylates Bax and promotes its mitochondrial localization during neuronal apoptosis. *co-first authors J. Neuroscience 24: 9993-10002, 2004.

70. Precht, TA, RA Phelps, DA Linseman, BD Butts, RJ Bouchard, SS Le, TA Laessig, and KA Heidenreich. Bax translocation to mitochondria is triggered by permeability transition pore opening in cerebellar granule neurons undergoing apoptosis. Cell Death and Differentiation, 12: 255-265, 2005.

14

71. Zimmermann, AK, FA Loucks, SS Le, BD Butts, M McClure, RJ Bouchard, KA Heidenreich, DA Linseman. Bcl-2 interacting mediator of cell death (Bim) induces cerebellar granule neuron apoptosis via a mechanism that is independent of Bcl-2 antagonism. J. Neurochem.94: 22-36, 2005.

72. Butts BD, HR Hudson, DA Linseman, SS Le , and KA Heidenreich. Proteasome inhibition elicits a biphasic effect on neuronal apoptosis via differential regulation of pro-survival and pro-apoptotic transcription factors. Mol. Cell. Neurosci. 30: 279-289, 2005.

73. Le, SS, FA Loucks, H Udo, S Richardson-Burns, RA Phelps, RJ Bouchard, H Barth, K Aktories, KL Tyler, ER Kandel, KA Heidenreich, and DA Linseman. Inhibition of Rac GTPase triggers a c-jun -and Bim-dependent mitochondrial apoptotic cascade in cerebellar granule neurons. J. Neurochem. 94: 1025-1039, 2005.

74. Antonescu, CN, C Huang, Z Liu, PA Eyers, P Cohen, KA Heidenreich, PJ Bilan, A Klip. Reduction of insulin-stimulated glucose uptake in L6 myotubes by the protein kinase inhibitor, SB203580, is independent of p38 MAPK activity. Endocrinology 146: 3773-3781, 2005.

75. Zhang, W, S Patil, B Chauhan, S Guo, D Powell, J Le, A Klotsas, X Xiao, R Franks, KA Heidenreich, MP Sajan, RV Farese, D Beer-Stoltz, P Tso, S-H Koo, M Montminty, and TG Unterman. FoxO1 regulates multiple metabolic pathways in the liver: effects on gluconeogenic, glycolytic and lipogenic gene expression. J. Biol. Chem. 281: 10105-10117, 2006.

76. Brewster JL, Linseman DA, Bouchard RJ, Loucks FA, Esche E, Precht T, and Heidenreich KA. Endoplasmic reticulum stress and trophic factor withdrawal activate distinct signaling cascades that converge at GSK-3b to trigger mitochondrial apoptosis in neurons. Mol. Cell. Neurosci. 32:242-253, 2006.

77. Allen, MP, S M Nielsen-Preiss, M Xu, DA Linseman, JE Pawlowski, R Bouchard, BC Varnum, KA Heidenreich, and ME Wierman. Adhesion related kinase induction of GnRH neuronal migration involves PI-3kinase stimulation of Rac activity. Endocrinology 148(6):2806-2814, 2007.

78. Farias, SE, S Zarini, T Precht, RC Murphy, and KA Heidenreich. Transcellular biosynthesis of cysteinyl-leukotrienes in the rat neuronal and glial cells. J. Neurochem. 103 (4): 1310-1318, 2007.

79. Klionsky, DJ et al. Guidelines for monitoring autophagy in higher eukaryotes. Autophagy 4 (2): 151-175, 2008.

80. Farias, SE , M Basselin, L Chang, KA Heidenreich, SI Rapoport, and RC Murphy. Simultaneous formation of eicosanoids and docosanoids following global ischemia, measured in high-energy microwaved rat brain. J. Lipid Res. 49: 1990-2000, 2008.

81. Mona Bains and KA Heidenreich. Live-cell imaging of autophagosome-lysosome fusion in primary neurons. Methods of Enzymology: Autophagy 253, ed D.L. Klionsky Invited chapter, 141-154, 2009.

82. Bains, M, ML Florez-McClure, and KA Heidenreich. IGF-I blocks autophagic cell death of Purkinje neurons by increasing the turnover of autophagic vesicles. J. Biol. Chem 284: 20398-20407, 2009.

83. Farias, SE, LC Frey, RC Murphy, and KA Heidenreich. Blockade of leukotriene production reduces brain injury following experimental TBI. J. Neurotrauma. 26: 1-10, 2009.

84. Bains, M, V Zaegel, J Mizeberge, and KA Heidenreich. IGF-I stimulates Rab7/RILp interaction during neuronal autophagy. Neuroscience Letters 488: 112-117, 2011.

85. Farias, SE, KA Heidenreich, RC Murphy, and EE Moore. Lipid mediators in cerebral spinal fluid of traumatic brain injured patients. J. of Trauma March, ahead of print, 2011.

86. Hankin, JA, S Farias, RM Barkely, KA Heidenreich, LC Frey, K Hamazaki, HY Kim, and RC Murphy.

15

MALDI Mass Spectrometric Imaging of Lipids in Rat Brain Injury Models. J. Amer. Soc. Mass Spectrometry 22: 1014-1021, 2011.

87. Frey, LC, S Farias, K Hasebroock, A Lepkin, K Youmans, S Zarini , N Serkova, RC Murphy, and KA Heidenreich. Blockade of injury-related production of leukotrienes reduces focal brain swelling, blood-brain-barrier disruption, and neurological dysfunction after experimental traumatic brain injury. J. Neurotrauma (under revision).

88. Klionsky, DJ et al. Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy 8 (4): 1-100, 2012.

89. Serbedzija,P, and C Corser-Jensen, and K A Heidenreich. An improved method for localizing and quantifying blood-brain-barrier disruption. J. Neurosci. Methods. (under revision)

90. Corser-Jensen, C.E., D.J. Goodell, P. Šerbedžija, R.K. Freund, and K.A. Heidenreich. Inhibition of leukotriene production protects against secondary brain damage and cognitive deficits induced by traumatic brain injury. Experimental Neurology 7-16, 2014 91. Heidenreich, K.A. and C.E. Corser-Jensen. 5-Lipoxygenase Activating Protein (FLAP) inhibitors as targeted pharmalogical therapies for neuroinflammation. World Journal of Biological Chemistry (in press). 92. Heidenreich, K.A. editor, New Therapies for Traumatic Brain Injury: Prevention of Secondary Brain Damage and Enhancement of Repair and Regeneration, Elsevier (in preparation). ABSTRACTS: 1. Heidenreich KA, ED Hendley: Photoaffinity labeling of noradrenergic binding sites with 3H –norepinephrine. Soc Neurosci 3:457, 1977.

2. Heidenreich KA, GA Weiland, PB Molinoff: Characterization of agonist binding to -adrenergic receptors in rat lung membranes. Soc Neurosci 6:853, 1980.

3. Zahniser NR, KA Heidenreich, and PB Molinoff: ATP- or GTP-induced increase in 3H-ADTN binding to rat striatal dopamine receptors is abolished by UV irradiation. Soc Neurosci 6:237, 1980.

3. Heidenreich KA, B Goens NR Zahniser: Subunit structure of insulin receptors in rat brain. Soc Neurosci 8:978, 1982.

4. Heidenreich KA, JM Olefsky: Internalization and intracellular degradation of insulin receptors in adipocytes. Endocrine Soc #820:285, 1983.

5. Heidenreich KA: Insulin receptor binding and internalization in cloned cell lines from rat central nervous system. Diabetes 33(1):58A, 1984.

6. Heidenreich KA: The Mr difference between insulin receptors in brain and peripheral target tissues is due to variation in carbohydrate content. Diabetes 34(1):56A, 1985.

7. Heidenreich KA, PR Gilmore, DP Figlewicz, GR Freidenberg: The glycosylation of IGF-I receptors differs in human brain and placenta. Diabetes 35(1):60A, 1986.

8. Heidenreich KA: The structure of receptors for insulin and IGF-I in nervous tissue. The 3rd International Symposium on Insulin Receptors, p. 2, 1986.

9. Heidenreich KA, PR Gilmore, and TW Garvey: Insulin receptors and glucose transport in primary neuronal cultures. Diabetes 36(1):149A, 1987.

16

10. Heidenreich KA, PR Gilmore, E Hatada: Peptide mapping and Northern blot analysis of insulin receptors in brain and adipocytes. Soc Neurosci 13:1021, 1987.

11. Heidenreich KA, R Monzon, S Toledo: Insulin stimulates protein synthesis and S6 kinase activity in cultured neurons. Diabetes 37(1):34A, 1988.

12. Heidenreich KA: Functional properties of the CNS subtype of insulin receptor. Symposium on the Action of Insulin and Related Growth Factors in Diabetes Mellitus 1988.

13. Heidenreich KA: The structure and function of neuronal insulin receptors. Amer Soc for Neurochem 20(1):208, 1989.

14. Moises RS, SP Toledo, KA Heidenreich: Pertussis toxin has differential effects on insulin action in BC3H1 myocytes. Diabetes 38(1):18A, 1989.

15. Heidenreich KA, SP Toledo: Insulin increases protein kinase C activity in both cytosolic and membrane fractions of cultured fetal neurons. Diabetes 38(1):65A, 1989.

16. Kenner KA, KA Heidenreich: Regulation of tyrosine phosphorylation by insulin and IGF-I in cultured fetal neurons. Soc Neurosci 15:708, 1989.

17. Kenner KA, KA Heidenreich: In vivo regulation of tyrosine phosphorylation in rat brain. Diabetes 39(1):1990.

18. Howard MJ, KA Heidenreich, TP Rothman, MD Gershon. Effects of growth factors on neuronal differentiation by neural crest cells. Soc Neurosci 16:1990.

19. Kenner KA, Heidenreich KA: Tyrosine phosphorylation of a 70 kDa protein by insulin and insulin-like growth factors in cultured fetal neurons. Soc Neurosci 16:1990.

20. Moises RS, KA Heidenreich: Glucose impairs the expression of inhibitory guanine nucleotide biding Protein (Gi) in cultured BC3H-1 myocytes. Proceeding of the XII Congresso Panamericano de Endocrinology 347:1990.

21. Kenner KA, KA Heidenreich: Insulin and IGFs stimulate receptor autophosphorylation and tyrosine phosphorylation of a 70 kDa substrate in intact fetal chick neurons. J Cell Biol 15B:56, 1991.

22. Kenner KA, J Kusari, KA Heidenreich: Analysis of insulin receptor cDNA sequence from human brain. The Endocrine Society 433, 1992.

23. Heidenreich KA, LJ Robinson: Insulin and IGF-I induce rapid and sustained changes in c-fos mRNA expression in cultured fetal neurons. Soc Neurosci 17:1992.

24. Heidenreich KA: Insulin and IGF-I receptor signaling in cultured neurons. NY Acad Sci Symp 1992. 25. Heidenreich KA, LJ Robinson: Insulin and IGF-I activate c-fos transcription in fetal neurons by a PKC-dependent pathway. Diabetes 42(1), 1993.

26. Begum N, LJ Robinson, B Draznin, KA Heidenreich: Protein phosphatase 1 and 2A activities in cultured fetal chick neurons: Developmental expression and regulation by insulin. The Endocrine Society 1993.

27. Heidenreich KA, LJ Robinson, JW Leitner, B Draznin: Insulin and insulin-like growth factor I activate p21Ras in cultured fetal neurons. Soc Neurosci 18:1993.

28. Hurlbert MS, F Adams, J Kummer, F Kaddis, CR Freed, KA Heidenreich: Use of genetically-altered

17

fibroblasts to provide growth factors to fetal dopaminergic neurons grafted into rat striatum. Copper Mountain Pharmacology Retreat, November 1994.

29. Kummer JL, JE Reusch, KA Heidenreich: Insulin inhibits a novel mitogen-activated protein (MAP) kinase in cultured fetal neurons. Fifth International Insulin and IGF Symposium, March 1995.

30. Kummer JL, WM Zawada, CR Freed, KA Heidenreich: Insulin-like growth I (IGF-I) acts synergistically with basic fibroblast growth factor (bFGF) to upregulate IGF binding proteins (IGFBPs) in fetal rat mesencephalic cultures. The Endocrine Society 1995.

31. Hurlbert MS, JL Kummer, CR Freed, KA Heidenreich: Rat-1 fibroblasts genetically modified to express human IGF-I enhance the survival of fetal rat mesencephalic dopamine neurons in culture. The Endocrine Society 1995.

32. Kummer JL, KA Heidenreich: Insulin inhibits p38 mitogen-activated protein kinase in cultured fetal neurons. Soc Neurosci 1995.

33. Kummer JL, AK Bauer, KA Heidenreich: Inhibition of p38 MAP kinase by insulin in fetal neurons. The Endocrine Society 1996.

34. Heidenreich KA, PM Sharma, PK Rao, JL Kummer: Regulation of p38 MAP kinase activity by insulin and Ras in Rat-1 fibroblasts. Am Soc Biochem & Mol Biol 1996.

35. Kummer JL, PK Rao, KA Heidenreich: p38 MAP kinase mediates apoptosis induced by withdrawal of trophic factors. The Endocrine Society 1997.

36. Zawada WM, MK Meintzer, CR Freed, L Shapiro, KA Heidenreich: Apoptosis induced by serum-withdrawal in embryonic mesencephalic cultures is mediated by p38 MAP kinase. Soc Neurosci 1997.

37. Shapiro L, AJ Puren, P Razeghi, KA Heidenreich, MK Meintzer, CA Dinarello: IL-18 stimulates production of HIV in U1 cells with dependence on tumor necrosis factor, IL-6, and the p38 mitogen activated protein (MAP) kinase. Cytokine Meetings 1997.

39.Wierman ME, K Schneider, MK Meintzer, C Zeng, X Xiong , KA Heidenreich: Growth arrest specific gene 6 (Gas6)/adhesion related kinase (Ark) signaling in GnRH neurons: Control of GnRH transcription and protection from apoptosis. WSCI 1998.

40. Pugazhenthi S, T Boras, KA Heidenreich, JE-B Reusch: IGF-1 regulation of CREB transactivation in PC-12 cells: Contributions from redundant signaling pathways. American Diabetes Association 1998.

41. Meintzer MK, WM Zawada, J Sabeti, CR Freed, KA Heidenreich: Inhibitors of p38 MAP kinase block neuronal apoptosis. The Endocrine Society 1998.

42. Xiong X, C Zeng, K Schneider, MK Meintzer, KA Heidenreich, ME Wierman: Regulation of neuronal GnRH transcription and apoptosis by growth arrest specific gene 6 (Gas6)/adhesion related kinase (Ark). The Endocrine Society 1998.

93. Heidenreich KA: The p38 MAP kinase pathway and cellular apoptosis. The Endocrine Society (symposium speaker abstract) 1998.

94. Sable CL, MK Meintzer, KA Heidenreich: Regulation of apoptosis in rat cerebellar granule neurons. The Endocrine Society 1999.

95. Pugazhenthi S, E Miller, C Sable, KA Heidenreich, L Boxer, J E-B Reusch: Induction of the Bcl-2 promoter by p38 b MAPK-mediated signaling pathway. The Endocrine Society 1999.

18

96. Zawada WM, MK Meintzer, C Sable, CR Freed, and KA Heidenreich. Pyridinyl imidazole compounds rescue dopaminergic neurons from apoptotic cell death. Soc. Neuroscience 1999.

97. Wierman ME, MP Allen, Z Fang, M Xu, C Zeng, KA Heidenreich, and S Tobet. Factors Regulating GnRH neurons. Invited speaker symposium, The Endocrine Society 2000

98. Zawada, WM, MK Meintzer, P Rao, J Marotti, X Wang, JE Esplen, ED Clark, CR Freed, and KA Heidenreich. Inhibitors of p38 MAP kinase increase survival of transplanted dopamine neurons. Soc. Neuroscience 2000.

99. Li, M, MP Allen, T Laessig, X Wang, ME Wierman, and KA Heidenreich. Myocyte enhancer factor-2 (MEF2) –A and –D regulate survival of rat cerebellar granule neurons. Soc. Neuroscience 2000.

100. Allen, MP, DA Linseman, KA Heidenreich, and ME Wierman, Growth arrest specific gene-6 (Gas6)/ adhesion related kinase (Ark) signaling meiates cytoskeletal remodeling and migration of gonadotropin releasing hormone (GnRH) neurons. Amer. Soc. Cell. Biol. 2000.

101. Heidenreich KA. Protein kinases that regulate neuronal survival and apoptosis. Joint meeting of Danish Soc. for Neurosci. and Soc. for Biochem and Mol. Biol. 2000.

102. McClure, ML and KA Heidenreich. The role of Fas signaling in neuronal apoptosis. UCHSC Research Forum, 2000.

103. Linseman, DA, M Li, MK Meintzer, T Laessig, and KA Heidenreich. IGF-I suppresses caspase activation and degradation of myocyte-enhancer factor-2D (MEF2-D) during apoptosis of cerebellar granule neurons. Endocrine Society 2001.

104. Allen, MP, DA Linseman, M Xu, KA Heidenreich, and ME Wierman. Cytoskeletal remodeling and migration of immortalized GnRH neurons is mediated by an adhesion related kinase (ARK)>RAC>p38 MAPK signaling pathway. Endocrine Society 2001.

105. Marches, F., KA Heidenreich, and T. Curiel. Pyridinylimidazoles inhibit intracellular T. gondii replication. International Congress on Toxoplasmosis. Freising, Germany, 2001.

106. Linseman, DA, T Laessig, MK Meintzer, M McClure, H, Barth, K Aktories, KA Heidenreich. Rac/Cdc42 function is required for cerebellar granule neuron survival. Gordon Conference, Oxford, UK

107. Allen, MP, DA Linseman, M Xu, KA Heidenreich, and ME Wierman. PI-3 kinase couples the adhesion related kinase (Ark) receptor to a Rac/p38 dependent migratory pathway in GnRH neurons. Society for Neuroscience, 2001.

108. Ahmadi, F, S Doolin, NR Zahniser, MP Grogan, KA Heidenreich, and WM Zawada. HNT- neurons are resistant to serum withdrawal and MPP+. Society for Neuroscience, 2001.

109. Linseman, DA, M Li, MK Meintzer, T Laessig, KA Heidenreich. Convergence of GSK-3 beta and c-jun signaling during apoptosis of cerebellar granule neurons. Society for Neuroscience, 2001.

110. McClure, ML, DA Linseman,, RJ Bouchard, TA Laessig, D Brenner, and KA Heidenreich. Suppression of death receptor signaling in cerebellar Purkinje neurons protects neighboring granule neurons form apoptosis. Society for Neuroscience, 2001.

111. McClure,ML.,DA Linseman, RJ Bouchard, TA Laessig, D Brenner, and KA Heidenreich. Suppression of death receptor signaling in cerebellar Purkinje neurons protects neighboring granule neurons form apoptosis. UCHSC Student Research Forum, October 12, 2001.

112. Linseman, DA, ML McClure, RA Phelps, RJ Bouchard, TA Laessig, SS Le, F Ahmadi, and KA

19

Heidenreich. Extrinsic and intrinsic death signaling in cerebellar neuronal apoptosis: the IGF-I connection. 8th International Conference on Neural Transplantation and Repair, Keystone, CO 2002.

113. Jones, SM, MK Meintzer, CR Freed, KA Heidenreich, and Zawada, WM. SC68376, a novel inhibitor of p38 MAP kinase rescues rat and human dopaminergic neurons from apoptotic cell death. 8th International Conference on Neural Transplantation and Repair, Keystone, CO 2002

114. Ahmadi, F., S. Doolin, NR Zahniser, MP McGrogan, KA Heidenreich, and MW Zawada. Effects of serum withdrawal and MPP+ on the HNT-neurons. 8th International Conference on Neural Transplantation and Repair, Keystone, CO 2002.

115. Linseman, DA, RA Phelps, RJ Bouchard, TA Laessig, SS Le, F Ahmadi, and KA Heidenreich. IGF-I inhibits Bim induction and the intrinsic death signaling cascade in cerebellar granule neurons. Keystone Symposium, Mitochondria and Pathogenesis, Copper, CO 2002.

116. McClure, ML, DA Linseman, RJ Bouchard, TA Laessig, FA Ahmadi, and KA Heidenreich, Suppression of death receptor signaling in cerebellar Purkinje neurons protects neighboring granule neurons from apoptosis via an IGF-I dependent mechanism. The Endocrine Society’s 84th Annual Meeting, 2002.

117. Linseman, DA, RA Phelps, RJ Bouchard, TA Laessig, SS Le, and KA Heidenreich. Insulin-like growth factor-I rescues cerebellar granule cerebellar neurons from apoptosis by blocking Bim induction and mitochondrial death signaling. The Endocrine Society’s 84th Annual Meeting, 2002.

118. McClure ML, D A Linseman, R Bouchard, T A Laessig, M K Meintzer, S S Le and K A Heidenreich. Identification of an autophagic death pathway in cerebellar Purkinje neurons downstream of death receptor signaling.. Society for Neuroscience 2002.

119. Ahmadi, F., DA Linseman, RJ Bouchard, S Jones, CR Freed, KA Heidenreich, and MW Zawada. Rotenone induces death of primary dopamine neurons by a caspase-dependent mechanism. Soc. for Neuroscience Annual meeting, 2002.

120. Linseman, DA, CM Bartley, MK Meintzer, SS Le, TA Laessig, RJ Bouchard, and KA Heidenreich. Ca2+/Calmodulin-dependent Protein kinase II Promotes Neuronal Survival by Inhibiting HDAC Repression of MED2D. The American Society for Cell Biology, 2002.

121. Linseman, DA, RA Phelps, TA Laessig, MK Meintzer, RJ Bouchard, SS Le, and KA Heidenreich. Bim induction and Bax translocation to mitochondria: key events in neuronal apoptosis that are targeted by neurotrophic factors. Keystone Symposium, Molecular mechanisms of Apoptosis, 2003.

122. Linseman DA, RA Phelps, TA Laessig, MK Meintzer, RJ Bouchard, SS Le, and KA Heidenreich. IGF-I blocks neuronal apoptosis by inhibiting Bim induction and Bax translocation to mitochondria. Gordon Research Conference, Insulin-like Growth Factors in Physiology and Disease, 2003.

123. Precht, TA, RA Phelps, DA Linseman, BD Butts, RJ Bouchard, SS Le, TA Laessig, and KA Heidenreich. Bax translocation to mitochondria is triggered by permeability transition pore opening in cerebellar granule neurons undergoing apoptosis. Society for Neuroscience 2003.

124. Le, SS, RJ Bouchard, TA Laessig, BD Butts, RA Phelps, KA Heidenreich, and DA Linseman. Inhibition of Rac GTPase induces Bim and activates a mitochondrial apoptotic casacade in cerebellar granule neurons. Society for Neuroscience 2003.

125. Butts, BD, DA Linseman, TA Precht, RA Phelps, TA Laessig, RJ Bouchard, SS Le, KL Tyler, KA Heidenreich. Glygogen synthase kinase –3b promotes Bax translocation to mitochondria during apoptosis of cerebellar granule neurons. Society for Neuroscience 2003.

126. Linseman, DA, CM Bartley, SS Le, TA Laessig, RJ Bouchard, and KA Heidenreich. CamKII promotes

20

cerebellar granule cell survival by blocking HDAC repression of MEF2 transcriptional activity. Society for Neuroscience 2003.

127. McClure ML, DA Linseman, CT Chu, RJ Bouchard, TA Laessig, SS Le, and KA Heidenreich. Neurotrophins and death receptors regulate autophagic death in cerebellar Purkinje neurons. Society for Neuroscience 2003.

128. Linseman DA, Butts BD, Precht TA, Phelps RA, Le SS, Laessig TA, Bouchard RJ, and Heidenreich KA Glycogen synthase kinase-3beta phosphorylates Bax and triggers its localization to mitochondria during neuronal apoptosis. Keystone Symposia – Apoptosis in Biochemistry and Structural Biology. 2004

129. Loucks FA, Zimmermann AK, Le SS, Bouchard RJ, Laessig TA, Heidenreich KA, and Linseman DA Antagonism of Bcl-2 reveals oxidative stress-dependent and –independent pathways for BH3-only-mediated neuronal apoptosis. Keystone Symposia – Apoptosis in Biochemistry and Structural Biology, 2004.

130. Hudson HR, Butts BD, DA Linseman, SS Le , and KA Heidenreich. Proteasome inhibition elicits a biphasic effect on neuronal apoptosis via differential regulation of pro-survival and pro-apoptotic transcription factors. Rocky Mountain Regional Neuroscience Meeting, June 2004.

131. Zimmermann AK, Loucks FA, Le SS, Bouchard RJ, Laessig TA, Heidenreich KA, and Linseman DA Bcl-2 interacting mediator of cell death (Bim) induces cerebellar granule neuron apoptosis via a mechanism that is independent of Bcl-2 antagonism. Rocky Mountain Regional Neuroscience Meeting, June 2004.

132. Chen, C, DA Linseman, BD Butts, RJ Bouchard, ML McClure, KA Heidenreich. GDNF protects primary dopamine neurons from MPP+induced toxicity by blocking diverse pathways to mitochondrial depolarization. Society for Neuroscience , San Diego, 2004.

133. Butts BD, HR Hudson, DA Linseman, SS Le , and KA Heidenreich. Proteasome inhibition elicits a biphasic effect on neuronal apoptosis via differential regulation of pro-survival and pro-apoptotic transcription factors. Society for Neuroscience , San Diego, 2004.

134. Zimmermann, AK, FA Loucks, SS Le, BD Butts, M McClure, RJ Bouchard, KA Heidenreich, DA Linseman. Bcl-2 interacting mediator of cell death (Bim) induces cerebellar granule neuron apoptosis via a mechanism that is independent of Bcl-2 antagonism. Society for Neuroscience , San Diego, 2004.

135. Chen, C, DA Linseman, BD Butts, RJ Bouchard, ML McClure, KA Heidenreich. GDNF protects primary dopamine neurons from MPP+induced toxicity by blocking diverse pathways to mitochondrial depolarization. Front Range Neuroscience Meeting, Fort Collins, CO, 2004.

136. Zimmermann, AK, FA Loucks, SS Le, BD Butts, M McClure, RJ Bouchard, KA Heidenreich, DA Linseman. Bcl-2 interacting mediator of cell death (Bim) induces cerebellar granule neuron apoptosis via a mechanism that is independent of Bcl-2 antagonism. Front Range Neuroscience Meeting, Fort Collins, CO, 2004. Poster award.

137. Precht TA, Phelps RA, Linseman DA, Butts BD, Bouchard RJ, and Heidenreich KA. The mPTP triggers Bax translocation to mitochondria during neuronal apoptosis. Keystone Symposia – Cellular Senescence and Cell Death, Keystone, CO, 2005.

138. Chen C, Linseman DA, Butts BD, Bouchard RJ, McClure ML, and Heidenreich KA. GDNF protects primary dopaminergic neurons from MPP+-induced toxicity by blocking diverse pathways to mitochondrial depolarization. Keystone Symposia – Cellular Senescence and Cell Death, Keystone, CO, 2005.

139. Butts BD, Hudson HR, Linseman DA, Le SS, and Heidenreich KA. The role of the proteasome in neuronal apoptosis. Keystone Symposia – Cellular Senescence and Cell Death, Keystone, CO, 2005.

140. Zimmermann AK, Loucks FA, Bouchard RJ, Heidenreich KA, and Linseman DA. Distinct inhibitors of

21

Bcl-2/Bcl-X(L) function elicit a common glutathione-sensitive pathway of neuronal death. Keystone Symposia – Cellular Senescence and Cell Death, Keystone, CO, 2005.

141. Linseman, DA, C Chen, BD Butts, RJ Bouchard, KA Heidenreich. GDNF protects primary dopamine neurons from MPP+induced toxicity by inhibiting multiple pathways of mitochondrial depolarization. 16th International Congress on Parkinson’s Disease, 2005.

142. Zimmermann, AK, FA Loucks, RJ Bouchard, KA Heidenreich, and DA Linseman. Role of complex III and ANT in GSH-sensitive neuronal death induced by inhibitors of Bcl-2/x(L). Soc. Neuroscience, 2005.

143. Precht TA, RA Phelps, DA Linseman, BD Butts, RJ Bouchard, and KA Heidenreich.. The mPTP Triggers Bax Translocation to Mitochondria During Neuronal Apoptosis. Rocky Mountain regional Neuroscience Group, Denver, CO, May 2005. Poster award

144. Zimmermann, AK, FA Loucks, RJ Bouchard, KA Heidenreich, and DA Linseman. Role of complex III and ANT in GSH-sensitive neuronal death induced by inhibitors of Bcl-2/x(L). Rocky Mountain Regional Neuroscience Group, Denver, CO, May 2005. Poster award

145. Zimmermann, AK, FA Loucks, RJ Bouchard, KA Heidenreich, and DA Linseman. Distinct inhibitors of Bcl-2/X(L) function elicit a common glutathione-sensitive pathway of neuronal death via oxidation of adenine nucleotide translocase. American Society for Neurochemistry 36th Annual meeting, 2005.

146. Zimmermann, AK, FA Loucks, RJ Bouchard, KA Heidenreich, and DA Linseman. Role of complex III and ANT in GSH-sensitive neuronal death induced by inhibitors of Bcl-2/x(L). Society for Neuroscience, 2005.

147. Precht TA, RA Phelps, DA Linseman, BD Butts, SS Lee, TA Laessig, RJ Bouchard, and KA Heidenreich.. The mPTP Triggers Bax Translocation During Neuronal Apoptosis. Front Range Neuroscience Group annual meeting, Fort Collins, December, 2005. Poster award .

148. Farias, SE, RC Murphy, and KA Heidenreich. Transcellular biosynthesis of cysteinyl-leukotrienes in the nervous system. Rocky Mountain Neuroscience Group Meeting, Aurora, CO, May, 2006. Oral presentation award.

149. Precht, T and KA Heidenreich. The role of mitochondrial fission in regulating intrinsic apoptosis of neurons. Rocky Mountain Neuroscience Group Meeting, Aurora, CO, May, 2006. Poster award.

150. Farias, SE, RC Murphy, and KA Heidenreich. Transcellular biosynthesis of cysteinyl-leukotrienes in the nervous system. Society for Neuroscience, Atlanta, October, 2006.

151. Precht, T and KA Heidenreich. The role of mitochondrial fission in regulating intrinsic apoptosis of neurons. Society for Neuroscience, Atlanta, October, 2006.

152. Precht, TA, J Schaak, and KA Heidenreich. Mitochondrial fission plays a role in neuronal apoptosis during trophic factor withdrawal. Rocky Mountain Neuroscience Group Meeting, Aurora, CO, May, 2007. Poster award.

153. Bains M, Florez-McClure M.L. and Heidenreich K.A. Insulin-like growth factor-I (IGF-I) blocks autophagic cell death by enhancing autophagic flux in cerebellar Purkinje neurons. 2007 Copper Mountain Retreat, Department of Pharmacology, UCHSC, October 2007

154. Bains, M, ML Florez-McClure, and KA Heidenreich. IGF-I blocks autophagic cell death by enhancing autophagic flux in cerebellar Purkinje neurons. Keystone Symposium Cell Death and Cellular Senescence, Breckenridge, CO, 2008.

155. Precht, TA and KA Heidenreich. hFis1 mediated changes in mitochondrial fission/fusion alters intrinsic neuronal apoptosis. Keystone Symposium Cell Death and Cellular Senescence, Breckenridge, CO, 2008.

22

156. Bains, M. and KA Heidenreich. Regulation of neuronal autophagy. Plenary talk Keystone Symposium Neurodegenerative Diseases: New Molecular Mechanisms, Keystone, CO, 2009.

157. Bains, M, V Zaegel, and KA Heidenreich. IGF-I prevents the accumulation of autophagic vesicles and cell death in Purkinje neurons by increasing the rate of autophagosome-lysosme fusion and degradation. VA Research Day, Denver, CO, 2009.

158. Zaegel V, M Bains, and KA Heidenreich. Dynein is necessary for the turnover of autophagic vesicles in SH-SY5Y neurons. Rocky Mountain Neuroscience Group Meeting, Aurora, CO, 2009.

159. Bains, M. and KA Heidenreich. IGF-I prevents the accumulation of autophagic vesicles and cell death in Purkinje neurons by increasing the rate of autophagosome-lysosme fusion and degradation. Rocky Mountain Neuroscience Group Meeting, Aurora, CO, 2009.

160. Rivera, N I, M Bains, and KA Heidenreich. The regulation of neuronal autophagy by insulin-like growth factor. Annual Biomedical Research Conference for Minority Students (ABRCMS), Phoenix, Arizona, 2009. (abstract chosen for oral presentation).

161. Rivera, N I, M Bains, and KA Heidenreich. The regulation of neuronal autophagy by insulin-like growth factor. The Endocrine Society Annual Meeting, San Diego, 2010.

162. Frey, LC, RC Murphy, and KA Heidenreich. Targeting the 5-lipoxygenase pathway in TBI. 4th Translational Neuroscience Conference, Denver, CO, 2011.

163. Goodell, DJ, J Mize-Berge, S Martin, RC Murphy, and KA Heidenreich. The role of microglia and astrocytes in the production of leukotrienes after traumatic brain injury. Building Research Achievement in Neuroscience (BRAiN) Symposium, Anschutz Medical Campus, CO, 2011 (1st Place Award).

164. Martin, SA, KA Heidenreich, and RC Murphy. Assays of leukotriene biosynthesis and pharmacological inhibition. Department of Pharmacology Retreat, Winter Park, CO, 2011.

165. Goodell, DJ, J Mize-Berge, S Martin, RC Murphy, and KA Heidenreich. The role of microglia and astrocytes in the production of leukotrienes after traumatic brain injury. Society for Neuroscience,

Washington, DC, 2011. 166. Šerbedžija, P, C. Corser-Jensen, RC Murphy, and KA Heidenreich Targeting the 5-lipoxygenase (5-

LO) pathway in traumatic brain injury. UC Denver Postdoctoral Research Symposium, Anschutz Medical Campus, Aurora, CO, 2012.

167. Foster, A., S. Martin, RC Murphy, and KA Heidenreich. Traumatic Brain Injury: Targeting the 5-

Lipoxygenase Pathway. Building Research Achievement in Neuroscience (BRAiN) Symposium, Anschutz Medical Campus, CO, 2012. Foster, A., S. Martin, RC Murphy, and KA Heidenreich. Investigating the Role of Leukotrienes in Traumatic Brain Injury, Annual meeting of the Society for Neuroscience, New Orleans, LA, 2012.

168. Corser-Jensen, CE, DJ Goodell, P Šerbedžija, RK Freund, KA Heidenreich. Prevention of TBI-induced

cognitive deficits using an inhibitor of leukotriene synthesis. Neuroscience Program Retreat, Winter Park, CO, 2012.

169. Foster, A., S. Martin, RC Murphy, and KA Heidenreich. Traumatic Brain Injury: Targeting the 5-

Lipoxygenase Pathway. Neuroscience Program Retreat, Winter Park, CO, 2012. 170. Šerbedžija, P, CE Corser-Jensen, DJ Goodell, RC Murphy, and KA Heidenreich. Does inhibition of the

5-LO leukotriene synthesis pathway with MK-886 prevent or ameliorate disruption of the blood-brain barrier and edema following fluid percussion injury? Front Range Neuroscience Group Annual Meeting, Fort

23

Collins, CO, December, 2012. 171. Corser-Jensen, C.E., D.J. Goodell, P. Šerbedžija, R.K. Freund, and K.A. Heidenreich. A 5-

lipoxygenase activating protein (FLAP) inhibitor attenuates secondary brain damage and cognitive deficits induced by experimental traumatic brain injury. The 3rd Annual Traumatic brain injury Conference, Washington, D.C., March 6, 2013.

172. Graham, J, G. Miknis, and KA Heidenreich. C2D2 and University of Colorado School of Medicine: A

Case study in collaboration. CSU Ventures Innovation Symposium, Fort Collins, CO, April 12th, 2013. 173. Foster, A. S. Martin, R.C. Murphy, and KA Heidenreich. Traumatic Brain Injury: Targeting the 5-

Lipoxygenase Pathway. UC Denver Research and Creative Activities Symposium, Denver, CO, April 19,,

2013. 174. Corser-Jensen, C.E., D.J. Goodell, P. Šerbedžija, R.K. Freund, and K.A. Heidenreich. Cognitive

deficits after traumatic brain injury are attenuated by blocking leukotriene production. National Clinical and Translational Sciences Predoctoral Programs Meeting, Mayo Clinic Campus, Rochester, MN, May 5-7, 2013.

175. Corser-Jensen, C.E., D.J. Goodell, P. Šerbedžija, R.K. Freund, and K.A. Heidenreich. Cognitive deficits after traumatic brain injury are attenuated by blocking leukotriene production. Rocky Mountain Regional Neuroscience Group Meeting, Denver, CO, May 2013.

176. Corser-Jensen, C.E., D.J. Goodell, P. Šerbedžija, R.K. Freund, and K.A. Heidenreich. Blockade of leukotriene production after fluid percussion injury mitigates deficits in hippocampal synaptic plasticity and learning and memory. National Neurotrauma Society Meeting, Nashville, TN, August 4-7, 2013.

177. Foster, A., C.E. Corser-Jensen, and KA Heidenreich. Establishing a mouse concussion model to investigate a novel pharmacological intervention for traumatic brain injury. ABRCMS Student Travel Award, 2013 Annual Biomedical Research Conference for Minority Students (ABRCMS), Nashville, TN, November 13 – 16, 2013.

178. Miknis, G., T. Opgenorth, R. M. Williams, J. Graham, S. Stevens, D. Clausen1, K.A. Heidenreich, R.

Murphy, and S. Keenan. Promoting Colorado Drug Discovery Research. Academic Drug Discovery Conference 2013, Nashville Music City Center, Nashville, TN, October 9-11, 2013.

179. CE Corser-Jensen, DJ Goodell, RK Freund, P Serbedzija, KA Heidenreich. A novel anti-inflammatory

approach to attenuate secondary injury and cognitive deficits after experimentalTBI. The 10th World Congress on Brain Injury. San Francisco, CA, March 19-22, 2014.

180. CE Corser-Jensen, AY Foster, S Feely, RK Freund, KA Heidenreich. Neuroinflammation in a closed

head injury model of traumatic brain injury. Translational Science 2014. Washington, D.C., April 9-11, 2014. 181. CE Corser-Jensen, AY Foster, RK Freund, KA Heidenreich. Prolonged neuroinflammation following a

single closed head injury (CHI) in mice. The 4th Annual Traumatic Brain Injury Conference. Washington D.C., April 16-17, 2014.

182. CE Corser-Jensen, AY Foster, KA Heidenreich. Prolonged neuroinflammation in the absence of overt

blood-brain barrier disruption following a single closed head injury (CHI) in mice. Keystone Symposium: Neuroinflammation in Diseases of the Central Nervous System. Taos,NM, January 25-30, 2015.

183. AG Blood, CE Corser-Jensen, KA Heidenreich. Prolonged neuroinflammation following a single closed

head injury (CHI) in mice. Western Student Medical Research Forum. Carmel, CA, January 29-31, 2015.

24

Past Research Funding: Department of Defense USAMRC #03281009 “Signaling Pathways that Mediate Neurotoxin-Induced Death of Dopamine Neurons” Kim A. Heidenreich-Principal Investigator Total Award: $1,342,395 (9/1/03-8/31/08) VA Merit Award "Stress-Activated Protein Kinases and the Control of Neuronal Apoptosis" K.A. Heidenreich – Principal Investigator Total Award: $658,400 (4/1/01-3/31/06) VA Research Enhancement Award “Mechanism and Prevention of Cell Death in Neurodegenerative Diseases” Kenneth L. Tyler-Program Director (K.A. Heidenreich,Co-Investigator) Total Award: $1,100,000 (10/1/98-9/31/04) Department of Defense AIBS#980281 “Protein Kinase Pathways That Regulate Neuronal Survival and Death” K.A. Heidenreich-Principal Investigator Total Award: $474,713 (8/1/99-8/31/04) NIH RO1 “Improving Survival of Transplanted Dopamine Neurons” K.A. Heidenreich-Principal Investigator Total Award: $791,443 (2/1/00-1/31/05) VA Merit Award "Insulin and IGF Regulation of p38 MAP Kinase and Neuronal Survival" K.A. Heidenreich – Principal Investigator Total Award: $465,709 (4/1/97-3/31/2001) NIH Spore Pilot Project "IGF and NK-kB Signaling Pathways that Regulate Proliferation and Apoptosis in Lung Cancer Cells" K.A. Heidenreich – Co-Principal Investigator Total Award: $20,000 (2/1/97-1/31/98) VA Merit Award "Molecular Mechanisms of Insulin and IGF Signaling in Neurons" K.A. Heidenreich – Principal Investigator Total Award: $396,700 (4/1/92-8/31/96) Juvenile Diabetes Foundation (#190689) "Insulin Regulation of Neuronal Protein Kinase C" K.A. Heidenreich – Principal Investigator Total Award: $100,000 (9/1/90-8/31/92) National Institutes of Health (R01 DK38071) "The Processing and Regulation of Insulin Receptors in Cultured Muscle Cells" K.A. Heidenreich – Principal Investigator Total Award: $244,257 (9/1/87-4/30/91) National Institutes of Health (Training Grant) "Training Program in Diabetes" K.A. Heidenreich – Co-investigator (8/1/83-6/30/91) Jerrold Olefsky – Program Director National Science Foundation (BNS 8742067) "The Structure and Function of Insulin Receptors in Brain"

25

K.A. Heidenreich – Principal Investigator Total Award: $145,286 (8/1/86-12/31/89) American Diabetes Foundation (Feasibility Grant) "Glucose Transport in Primary Neuronal Cultures" K.A. Heidenreich – Principal Investigator Total Award: $70,000 (7/1/87-12/31/89) Juvenile Diabetes Foundation (Career Development Award) Total Award: $120,000 (7/1/86-6/30/89) National Science Foundation "Research Education for Undergraduates" fellowship K.A. Heidenreich – Sponsor Total Award: $4,000 (6/1/87-9/1/87) Juvenile Diabetes Foundation (Research Grant) "Insulin Receptors in the Central Nervous System) K.A. Heidenreich – Principal Investigator Total Award: $60,000 (9/1/84-8/31/86) NIH Biomedical Research Support Grant "Insulin Receptors in Cell lines Cloned from Rat Central Nervous System" K.A. Heidenreich – Principal Investigator Total Award: $2,727 (7/1/84-6/30/85) NIH Biomedical Research Support Grant "Insulin Receptors in the Central Nervous System" K.A. Heidenreich – Principal Investigator Total Award: $3,647 (7/1/83-6/30/84)